<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00412620</url>
  </required_header>
  <id_info>
    <org_study_id>M06-816</org_study_id>
    <nct_id>NCT00412620</nct_id>
  </id_info>
  <brief_title>An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia</brief_title>
  <official_title>Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to explore the safety and efficacy of ABT-925 involving
      patients who meet the DSM-IV-TR (Diagnostic and Statistical Manual of Medical Disorders,
      Fourth Edition Text Revision) criteria for an acute exacerbation of schizophrenia or
      schizoaffective disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To explore the safety and efficacy of ABT-925 treatment at three different doses for 6 weeks
      compared with placebo in subjects with a diagnosis of acute exacerbation of schizophrenia or
      schizoaffective disorder according to DSM-IV-TR criteria (Diagnostic and Statistical Manual
      of Mental Disorders, Fourth Edition Text Revision).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Positive and Negative Syndrome Scale</measure>
    <time_frame>Assessed at screening and weekly from baseline through week 42/premature discontinuation</time_frame>
    <description>The PANSS (The Positive and Negative Syndrome Scale) assesses the severity of symptoms of schizophrenia over the preceding seven days. The PANSS items are divided into positive, negative, and general psychopathology factors. The PANSS total score is the score of all 30 PANSS items taken together.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brief Psychiatric Rating Scale</measure>
    <time_frame>Assessed at screening and weekly from baseline through week 42/premature discontinuation</time_frame>
    <description>Subscale of PANSS (The Positive and Negative Syndrome Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Severity score</measure>
    <time_frame>Assessed at screening and weekly from baseline through week 42/premature discontinuation</time_frame>
    <description>Assesses the overall, absolute degree of illness at any point in time (refer to the degree of illness at the time of the visit and during the week prior to the visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calgary Depression Scale for Schizophrenia Total score</measure>
    <time_frame>Assessed at screening and weekly from baseline through week 42/premature discontinuation</time_frame>
    <description>The CDSS (Calgary Depression Scale for Schizophrenia Total score) consists of items designed to assess the severity of symptoms of depression in the presence of schizophrenia such as depressed mood, hopelessness, guilt, and insomnia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative Symptom Assessment</measure>
    <time_frame>Assessed at screening and weekly from baseline through week 42/premature discontinuation</time_frame>
    <description>The NSA (Negative Symptom Assessment) is a 16-item instrument plus a one-item global rating designed to measure specific negative symptoms in schizophrenia</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1 Part 1 - ABT-925</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1 Part 2 - ABT-925</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - ABT-925</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-925</intervention_name>
    <arm_group_label>Group 1 Part 1 - ABT-925</arm_group_label>
    <arm_group_label>Group 1 Part 2 - ABT-925</arm_group_label>
    <arm_group_label>Group 2 - ABT-925</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Sugar Pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject has a current primary diagnosis of schizophrenia or schizoaffective
             disorder; specifically, an acute exacerbation with prominent &quot;active phase&quot; symptoms,
             as described in Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
             Text Revision criteria (and confirmed by the Structured Clinical Interview for
             Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision).
             Subjects with schizophrenia may belong to any of the following subtypes: paranoid,
             disorganized, catatonic, or undifferentiated.

          -  The subject has a The Positive and Negative Syndrome Scale total score of greater than
             or equal to 60.

          -  The subject has a score of greater than 4 (&quot;moderate&quot;) on at least 2 out of the
             following 5 The Positive and Negative Syndrome Scale positive symptoms: delusions,
             conceptual disorganization, hallucinatory behavior, grandiosity,
             suspiciousness/persecution.

          -  The subject is between 18 and 65 years old inclusive at the time of randomization.

          -  The subject has a reliable caregiver (if applicable) or an identified responsible
             (e.g., family member, social worker, nurse) who will support him/her to ensure
             compliance with treatment and outpatient visits. In addition, the subject must have an
             adequate place of residence.

          -  The subject agrees to be hospitalized for the duration of the Taper off/Washout Period
             and at least the first fourteen days of the Double-blind Period.

        Exclusion Criteria:

          -  The subject has a body mass index greater than 35.

          -  The subject has any condition that in the opinion of the investigator is likely to
             place him/her at an unacceptable safety risk by entering the study or by treatment
             with ABT-925.

          -  The subject has a diagnosis of one or more of the following conditions: another
             primary Axis I disorder, including schizophreniform disorder, bipolar disorder or
             major depressive disorder; comorbid Axis II diagnoses, including borderline
             personality disorder and mental retardation. (Note: a diagnosis of depression not
             otherwise specified is acceptable for inclusion into the study).

          -  The subject has a diagnosis of substance or alcohol disorder (abuse/dependence
             according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
             Text Revision criteria), excluding nicotine, within one (1) month prior to the
             beginning of the Screening Period, or in the opinion of the investigator, a disorder
             that will interfere with the conduct of the study.

          -  The subject has a history of substance-induced psychotic disorder in the previous 6
             months.

          -  The subject has evidence suggestive of treatment-resistant schizophrenia (i.e., lack
             of significant clinical improvement despite adequate courses and doses of at least two
             different antipsychotic medications during the previous 2 years; or adequate use of
             clozapine indicated for treatment-resistant schizophrenia).

          -  The subject has serious violent, homicidal or suicidal ideation in the opinion of the
             investigator.

          -  The subject has a screening QT interval corrected by Bazett formula interval of
             greater than 430 msec if male and greater than 450 msec if female.

          -  The subject's Liver Function Tests (Aspartate aminotransferases, Alanine
             aminotransferase or total bilirubin levels) are not within normal limits at screening.

          -  The subject has a diagnosis, history, or a positive serological result suggestive of
             liver disease including but not limited to hepatitis and Gilbert's Syndrome.

          -  The subject has received any of the following treatments within the time periods
             described: mood stabilizers or antidepressants during the 30 days prior to Screening;
             electroconvulsive therapy during the 3 months prior to Screening; clozapine during 60
             days prior to Screening.

          -  The subject is currently receiving treatment with oral psychotropic medications or has
             received depot neuroleptics within one inter-injection interval.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beatrice Rendenbach-Mueller, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5188</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4539</name>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <zip>90703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4175</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4553</name>
      <address>
        <city>Pico Rivera</city>
        <state>California</state>
        <zip>90660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4173</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4565</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4177</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4168</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4567</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78754</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4176</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4371</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5227</name>
      <address>
        <city>Buenos Aires</city>
        <zip>CP1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5226</name>
      <address>
        <city>Cordoba</city>
        <zip>X5009BIN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5224</name>
      <address>
        <city>La Plata</city>
        <zip>1900</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4305</name>
      <address>
        <city>Guadalajara</city>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4304</name>
      <address>
        <city>Mexico City</city>
        <zip>CP 03740</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4303</name>
      <address>
        <city>Mexico City</city>
        <zip>CP 14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 4298</name>
      <address>
        <city>Monterrey</city>
        <zip>CP 64000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2006</study_first_submitted>
  <study_first_submitted_qc>December 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2006</study_first_posted>
  <last_update_submitted>April 25, 2011</last_update_submitted>
  <last_update_submitted_qc>April 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Beatrice Rendenbach-Mueller, PhD, Project Director, Neuroscience/Anesthesia Department</name_title>
    <organization>Abbott Laboratories</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

